Phillip Minar, MD, MS
- Medical Director, Shubert-Martin Inflammatory Bowel Disease Center
- Program Director, Advanced Pediatric IBD Fellowship Training
- Professor, UC Department of Pediatrics
- phillip.minar@cchmc.org
- Board Certified
About
BA: Duquesne University, Pittsburgh, PA
MS: Clinical and Translational Research, University of Cincinnati, Cincinnati, OH
MD: Medical College of Wisconsin, Milwaukee, WI
Residency: Pediatrics, Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, WI
Fellowship: Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's, Cincinnati, OH
Certifications: General Pediatrics; Pediatric Gastroenterology
Interests
Pediatric inflammatory bowel disease; evidence-based care for children and young adults with IBD; sustained, prednisone-free clinical remission
Services and Specialties
Interests
Application of personalized medicine in the care of children and young adults with IBD through the discovery of surrogate biomarkers of intestinal inflammation; sensitive and specific pharmacodynamic biomarker, neutrophil CD64; innovative pharmacokinetic dosing platform, RoadMAB; personalized dosing of biologic therapies for patients with IBD; novel method to dose infliximab (guided by RoadMAB) from the start of treatment and throughout the maintenance phase to assess both the effectiveness and safety of model-informed precision dosing.
Research Areas
Locations (3)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Markers of Gut Inflammation in Pediatric Acute Pancreatitis. Pancreas. 2026; 55(6):e661-e662.
The Safety and Effectiveness of Early Anti-Tumor-Necrosis-Factor Therapy for Penetrating Crohn's Disease Complications in Children. American Journal of Gastroenterology. 2026.
Effectiveness and safety of ustekinumab in pediatric Crohn's disease: Results of the REALITI study. Journal of Pediatric Gastroenterology and Nutrition. 2026; 82(5):1242-1250.
Mo1634 BRIDGING DRUG EXPOSURE TO BIOCHEMICAL REMISSION: A PK/PD FRAMEWORK TO INDIVIDUALIZE INFLIXIMAB TARGET CONCENTRATIONS IN PEDIATRIC CROHN’S DISEASE. Gastroenterology. 2026; 170(6):s-1221-s-1222.
Mo1634 BRIDGING DRUG EXPOSURE TO BIOCHEMICAL REMISSION: A PK/PD FRAMEWORK TO INDIVIDUALIZE INFLIXIMAB TARGET CONCENTRATIONS IN PEDIATRIC CROHN’S DISEASE. Gastrointestinal Endoscopy. 2026; 103(5):s-1221-s-1222.
Machine Learning Modeling for Predicting Infliximab Pharmacokinetics in Pediatric and Young Adult Patients With Crohn Disease: Leveraging Ensemble Modeling With Synthetic and Real-World Data. Therapeutic Drug Monitoring. 2026; 48(1):98-104.
Model-Informed Deep Q-Networks to Guide Infliximab Dosing in Pediatric Crohn's Disease. Clinical Pharmacology and Therapeutics. 2026; 119(2):555-563.
Comment on a Risk Stratification Tool for Relapse After Intravenous-to-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases. American Journal of Gastroenterology. 2026; 121(1):101-102.
CAPTURE IBD: Advancing Precision Medicine in Pediatric IBD. Inflammatory Bowel Diseases. 2026; 32(1):188-190.
P0937 Antibiotic duration is not associated with healing of perianal fistulising complications of Crohn’s disease. Journal of Crohn's and Colitis. 2026; 20(Supplement_1):jjaf231.1118.
From the Blog
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey